ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 445,69
2,24%
Dow Jones
43 049,74
0,74%
DAX
20 216,19
1,54%
Brent Oil
76,39
-0,15%
Bitcoin
102 048,46
3,78%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cumberland Pharmaceutical Inc (CPIX)

  7. Cumberland Pharmaceutical Inc (CPIX) Actualités

CPIX

Cumberland Pharmaceutical (CPIX)

Cumberland Pharmaceutical Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CPIX
DateHeureSourceTitreSymboleSociété
31/12/202401h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPIXCumberland Pharmaceutical Inc
09/12/202423h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPIXCumberland Pharmaceutical Inc
09/12/202422h05PR Newswire (US)FDA APPROVES ACETADOTE® sNDANASDAQ:CPIXCumberland Pharmaceutical Inc
08/11/202423h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPIXCumberland Pharmaceutical Inc
07/11/202422h05PR Newswire (US)Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company UpdateNASDAQ:CPIXCumberland Pharmaceutical Inc
06/11/202423h21PR Newswire (US)CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYNASDAQ:CPIXCumberland Pharmaceutical Inc
05/11/202422h05PR Newswire (US)New Study Compares Caldolor® (ibuprofen injection) to ketorolacNASDAQ:CPIXCumberland Pharmaceutical Inc
31/10/202421h05PR Newswire (US)CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTSNASDAQ:CPIXCumberland Pharmaceutical Inc
06/08/202422h05PR Newswire (US)Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024NASDAQ:CPIXCumberland Pharmaceutical Inc
30/07/202422h05PR Newswire (US)CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTSNASDAQ:CPIXCumberland Pharmaceutical Inc
07/05/202422h05PR Newswire (US)Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company UpdateNASDAQ:CPIXCumberland Pharmaceutical Inc
30/04/202422h05PR Newswire (US)CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTSNASDAQ:CPIXCumberland Pharmaceutical Inc
02/04/202422h05PR Newswire (US)NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONSNASDAQ:CPIXCumberland Pharmaceutical Inc
05/03/202422h05PR Newswire (US)Cumberland Pharmaceuticals Reports Annual 2023 Financial ResultsNASDAQ:CPIXCumberland Pharmaceutical Inc
27/02/202422h05PR Newswire (US)CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTSNASDAQ:CPIXCumberland Pharmaceutical Inc
09/02/202423h27Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CPIXCumberland Pharmaceutical Inc
27/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CPIXCumberland Pharmaceutical Inc
15/12/202322h14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:CPIXCumberland Pharmaceutical Inc
14/12/202323h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CPIXCumberland Pharmaceutical Inc
06/12/202323h01Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CPIXCumberland Pharmaceutical Inc
07/11/202322h05PR Newswire (US)Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNASDAQ:CPIXCumberland Pharmaceutical Inc
31/10/202321h05PR Newswire (US)CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTSNASDAQ:CPIXCumberland Pharmaceutical Inc
10/10/202322h05PR Newswire (US)NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGENASDAQ:CPIXCumberland Pharmaceutical Inc
27/09/202316h55Dow Jones NewsCorrection to SEC Fines ArticleNASDAQ:CPIXCumberland Pharmaceutical Inc
27/09/202316h43Dow Jones NewsSEC Fines 5 Public Companies, Insiders Over Reporting FailuresNASDAQ:CPIXCumberland Pharmaceutical Inc
08/08/202322h05PR Newswire (US)Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023NASDAQ:CPIXCumberland Pharmaceutical Inc
01/08/202322h05PR Newswire (US)CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTSNASDAQ:CPIXCumberland Pharmaceutical Inc
26/06/202315h00PR Newswire (US)NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTSNASDAQ:CPIXCumberland Pharmaceutical Inc
22/06/202312h00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CPIXCumberland Pharmaceutical Inc
23/05/202315h00PR Newswire (US)CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSISNASDAQ:CPIXCumberland Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:CPIX

Dernières Valeurs Consultées

BIT
NSCIT0011915
GDF Suez
BIT
XIGB
Xtrackers India Governme...
COIN
TRXUSD
TRON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés